Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PBPV in Healthy Adults
NCT04087460Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Apr 2020
- Primary completion
- May 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Protein Based Pneumococcal Vaccine in pneumococcal infection (6 arms), sponsored by CanSino Biologics Inc. Primary endpoints: Safety indexes of solicited and unsolicited adverse reactions, Safety indexes of lab measures (Day 3, 8) at Day 8 and 1 more. Started Apr 2020; status: completed.
02
Drugs
Protein Based Pneumococcal Vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT04087460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04087460.